ロード中...
Pharmacokinetics of conivaptan use in patients with severe hepatic impairment
PURPOSE: Conivaptan is an intravenous dual V(1A)/V(2) vasopressin antagonist approved for the treatment of euvolemic and hypervolemic hyponatremia. Earlier studies showed that patients with moderate liver disease could be safely treated with conivaptan by reducing the dose by 50%, whereas patients w...
保存先:
| 出版年: | Drug Des Devel Ther |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2017
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5315214/ https://ncbi.nlm.nih.gov/pubmed/28243060 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S125459 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|